Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
Status:
Completed
Trial end date:
2018-08-06
Target enrollment:
Participant gender:
Summary
Sustained Viral Response following 12-week therapy (SVR 12) with sofosbuvir/ledipasvir in
transfusion-dependent patients with HCV genotype 1-6
Secondary Objective(s):
Assessment of transfusion requirements Adverse events Efficacy in treatment-naïve vs.
relapsers vs. null responders Efficacy in patients with advanced fibrosis/cirrhosis vs. F1,
F2 by elastography